Loading patent…
AssigneesThe General Hospital Corporation, Massachusetts Eye and Ear Infirmary
InventorsBruce D. Walker, Gaurav D. Gaiha, Elizabeth Rossin
Estimating the term…
A method of preventing or treating HIV in a subject includes selecting two or more HIV CTL epitopes from an HIV proteome that have a network score that meets a threshold value. The network score for a given epitope can be determined by generating at least one network representing protein structure, calculating a set of network parameters, combining the network parameters to determine a network score for each amino acid residue in the protein structure, generating a network score for each of a plurality of epitopes as a weighted linear combination of the amino acid residues of the epitopes, and selecting two or more epitopes according to their network score. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected HIV CTL epitopes.
A multi-epitope T cell immunogen composition comprising two highly networked human immunodeficiency virus (HIV) cytotoxic T lymphocyte (CTL) epitopes, wherein the two highly networked HIV CTL epitopes are human leukocyte antigen (HLA)-B*57 KAFSPEVIPMF (KF11) (SEQ ID NO:201) and HLA-B*57 TSTLQEQIGW (TW10) (SEQ ID NO:202), or wherein the amino acid sequences of the highly networked HIV CTL epitopes have at least about 75% to about 99% homology to the amino acid sequences of HLA-B*57 KF11 and HLA-B*57 TW10.
A multi-epitope T cell immunogen composition comprising two or more highly networked HIV CTL epitopes, wherein the two highly networked HIV CTL epitopes are HLA-B*57 KAFSPEVIPMF (KF11) (SEQ ID NO:201) and HLA-B*57 TSTLQEQIGW (TW10) (SEQ ID NO:202), and further comprising at least ten HIV CTL epitopes, wherein the ten HIV CTL epitopes are HLA-A*11 AVDLSHFLK (AK9) (SEQ ID NO:
A multi-epitope T cell immunogen composition comprising two highly networked HIV CTL epitopes HLA-B*57 KAFSPEVIPMF (KF11) (SEQ ID NO:201) and HLA-B*57 TSTLQEQIGW (TW10) (SEQ ID NO:202), or amino acid sequences having at least about 75% to about 99% homology to the amino acid sequences of HLA-B*57 KF11 of and HLA-B*57 TW10 and further comprising two highly networked HIV CTL epitopes restricted by HLA-E*101 and HLA-E*103, wherein the two highly networked HIV CTL epitopes are selected from HLA-E*101/E*103 SALSEGATP (SEQ ID NO:
An RNA vector comprising a multi-epitope T cell immunogen, wherein the vector comprises a sequence comprising two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score from 3.04 to 9.05.
A viral vector comprising a multi-epitope T cell immunogen, wherein the vector comprises a sequence comprising two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score from 3.04 to 9.05, and wherein the viral vector is selected from the group consisting of a human adenovirus, a rhesus adenovirus, adeno-associated virus, Gorilla adenovirus, modified Ankara virus, herpesvirus, and a cytomegalovirus (CMV) viral vector.
Dependencies are inferred from the claim text.